---
title: "ANIP: Q2 2026 delivered 26% revenue growth, led by Rare Disease and Cortrophin Gel's 43% surge"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295230809.md"
description: "Q2 2026 saw 26% revenue growth and 32% higher adjusted EBITDA, driven by Rare Disease and generics. Cortrophin Gel led with 43% growth, and guidance for 2026 was reaffirmed, projecting strong top- and bottom-line expansion.Original document: ANI Pharmaceuticals, Inc. [ANIP] Slides Release — Aug. 7 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-07T11:58:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295230809.md)
  - [en](https://longbridge.com/en/news/295230809.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295230809.md)
generator: "portal-rs"
---

# ANIP: Q2 2026 delivered 26% revenue growth, led by Rare Disease and Cortrophin Gel's 43% surge

Q2 2026 saw 26% revenue growth and 32% higher adjusted EBITDA, driven by Rare Disease and generics. Cortrophin Gel led with 43% growth, and guidance for 2026 was reaffirmed, projecting strong top- and bottom-line expansion.

Original document: ANI Pharmaceuticals, Inc. \[ANIP\] Slides Release — Aug. 7 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ANIP.US](https://longbridge.com/en/quote/ANIP.US.md)

## Related News & Research

- [Globeflex Capital L P Takes Position in ANI Pharmaceuticals, Inc. $ANIP](https://longbridge.com/en/news/296757387.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [DE: 3Q 2026 saw sales and profit growth, but FY 2026 guidance signals industry headwinds](https://longbridge.com/en/news/296475895.md)
- [88% of Nvidia's portfolio is invested in these 3 artificial intelligence (AI) stocks](https://longbridge.com/en/news/296341788.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**